Zilver PTX: Maintains efficacy in real life most challenging lesions?

Original Title: Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan 12-Month Results.
Reference: Hiroyoshi Yokoi et al. J Am Coll Cardiol Intv. 2016;9(3):271-277.

 

This multicenter prospective study carried out in Japan assessed the paclitaxel eluting stent Zilver PTX in an unselected real world population very different to that compliant with inclusion/exclusion criteria, usually included in randomized studies.

 
The Zilver PTX is the first DES approved to treat the superficial femoral artery. Previous results from a large randomized study and a complementary large single-arm study supported the safety and effectiveness of this stent in selected lesions.

 
In the present study, there were no exclusion criteria and all consecutive patients with symptomatic peripheral artery disease receiving Zilver PTX were enrolled. Clinical driven target lesion revascularization was defined as any reintervention on a ≥50% diameter lesion associated to symptom recurrence. The clinical benefit was defined as freedom from persistent symptoms, intermittent claudication or symptom worsening. And patency was assessed by Doppler.

 
907 patients were enrolled in 95 hospitals across Japan. The population presented numerous comorbidities including a high incidence of diabetes (58.8%), chronic kidney failure (43.8%) and critical limb ischemia (21.5%). Lesions were also complex, average length was 14.7 cm, 41.6% were total occlusions and 18.6% were instent restenosis.

 
At 12 months, the rate of clinically justified lesions free from reintervention was 91%, and clinical benefit rate was 87.7%. Primary patency rate reached 86.4%.

 

 

Conclusion
Despite lesions were far more challenging, outcomes in this study were similar to those of prior studies, which confirms the benefit of the Zilver PTX in the real world population.

 

Editorial Comment
The original studies on Zilver PTX had shown the superiority of this device vs. standard treatment (conventional balloon and conventional provisional stenting) or vs. conventional stents. This large post launch registry confirms the benefit in both more complex lesions and more complex patients.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...